^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | avutometinib (VS-6766) (BRAF inhibitor, MEK inhibitor, cRAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Results from the biomarker-driven basket trial of RO5126766 (CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma.
Published date:
05/30/2017
Excerpt:
Of the gynaecological cancers, 3/5 patients (60%) achieved a partial response (KRAS-mutant endometrial and ovarian cancer and BRAF-mutant ovarian). RO5126766 has shown exciting preliminary activity across a wide range of RAS- and RAF-mutated malignancies, with significant response rates in lung and gynaecological cancers.
DOI:
10.1200/JCO.2017.35.15_suppl.2506
Trial ID:
